Hedge fund manager Kyle Bass loses challenges to pharma patents |  | NEW YORK (Reuters) - Prominent hedge fund manager Kyle Bass's campaign to wipe out certain drug patents hit a roadblock on Monday when the U.S. Patent and Trademark Office declined to formally review two patents on Acorda Therapeutics Inc's flagship multiple sclerosis drug, Ampyra. | |  | |  |  | |  |  | Related Video | |  | |  | |  |  |  |  |  | A quick-fix on the day's news delivered when you want it. Register Today |  | |  |  |  | A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today |  | |  | » » MORE NEWSLETTERS |  | |
No comments:
Post a Comment